The activation of PPAR-γ in turn suppresses the expression and secretion of inflammatory factors, pro-inflammatory chemokines, which may reprogram the immune microenvironment of cancer to be less “inflamed”, consequently enabling resistance of cancer cells to immune-directed therapies (54). This evidence concerns the gene PPARG and cancer.